

MEDICAL DISCOVERIES INC

Form 10QSB/A

November 15, 2004

**Table of Contents**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 10-QSB/A**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended March 31, 2004

**TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number 0-12627

**MEDICAL DISCOVERIES, INC.**

\_\_\_\_\_  
(Exact name of Small Business Issuer as specified in its charter)

Utah

87-0407858

\_\_\_\_\_  
(State or other jurisdiction of incorporation or organization)

\_\_\_\_\_  
(I.R.S. Employer Identification No.)

738 Aspenwood Lane, Twin Falls, Idaho 83301

\_\_\_\_\_  
(Address of principal executive offices)

(208) 736-1799

\_\_\_\_\_  
(Issuer's telephone number, including area code)

N/A

\_\_\_\_\_  
(Former name, former address and former fiscal year, if changed since last report)

**APPLICABLE ONLY TO CORPORATE ISSUERS:**

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: As of May 12, 2004, there were 90,291,185 shares of the issuer's Common Stock outstanding.

Transitional Small Business Disclosure Format (check one): Yes  No

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act): Yes  No

---

## TABLE OF CONTENTS

### Explanatory Note

The purpose of this amendment on Form 10-QSB/A to the Quarterly Report on Form 10-QSB of Medical Discoveries, Inc. for the quarter ended March 31, 2004 is to restate our interim consolidated financial statements for the quarter ended March 31, 2004 and related disclosures as of and for the quarter ended March 31, 2004. Generally, no attempt has been made in this Form 10-QSB/A to modify or update other disclosures presented in the original report on Form 10-QSB except as required to reflect the effects of the restatement. The Form 10-QSB/A generally does not reflect events occurring after the filing of the Form 10-QSB or modify or update those disclosures, including the exhibits to the Form 10-QSB, affected by subsequent events. Information not affected by the restatement is unchanged and reflects the disclosures made at the time of the original filing of the Form 10-QSB on May 17, 2004. Accordingly, this Form 10-QSB/A should be read in conjunction with our filings made with the Securities and Exchange Commission subsequent to the filing of the original Form 10-QSB, including any amendments to those filings. The following items have been amended as a result of the restatement:

Part I Item 1. Financial Statements

Part I Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Part II Item 2. Changes in Securities

There are two principal changes in the restatement. The first is to correct our disclosure relating to extension of certain options. We initially reported that due to a change in the expiration date of certain options, the options would be subject to variable accounting treatment. We have since determined that the options are not subject to variable accounting treatment, but rather a remeasurement of the options as if they were newly granted. See Note 1 to the Consolidated Financial Statements for a further explanation. The second is to correct an error in the cumulative net loss from inception to date as reflected on the Statements of Operations. While we previously reported the correct cumulative net loss on the Statements of Cash Flows, the same figure as reported on the Statements of Operations was erroneous based on an apparent incorrect calculation in 1999, which error had been carried forward. We do not believe the difference to be material, but have elected to correct this error in the 2003 10-KSB and subsequent filings. In addition to the two principal changes outlined above, we have made other non-material adjustments in the financial statement disclosures to conform to the disclosures we will file with our Quarterly Report on Form 10-QSB for the quarter ended September 30, 2004.

For convenience and ease of reference, we are filing our quarterly report in its entirety with the applicable changes.

## PART I FINANCIAL INFORMATION

### ITEM 1. FINANCIAL STATEMENTS

The following financial statements are filed with this report:

Condensed Consolidated Balance Sheet as of March 31, 2004 (unaudited) and December 31, 2003 (unaudited)

Condensed Consolidated Statements of Operations for the three-month periods ended March 31, 2004 (unaudited) and March 31, 2003 (unaudited) and cumulative amounts since inception through March 31, 2004 (unaudited)

Condensed Consolidated Statements of Cash Flows for the three-month periods ended March 31, 2004 (unaudited) and March 31, 2003 (unaudited) and cumulative amounts since inception through March 31, 2004 (unaudited)

Notes to Unaudited Financial Statements

EXHIBIT 31

EXHIBIT 32

**Table of Contents**

MEDICAL DISCOVERIES, INC. AND SUBSIDIARIES  
(A DEVELOPMENT STAGE COMPANY)

CONDENSED CONSOLIDATED BALANCE SHEET  
As of March 31, 2004 and December 31, 2003  
(Unaudited)

	March 31, 2004	December 31, 2003
Current assets		
Cash	\$ 608,310	\$ 424,216
Prepaid expenses		11,331
Current portion of deferred charges		12,077
Total current assets	\$ 608,310	\$ 447,624
Current liabilities		
Accounts payable	\$ 2,200,019	\$ 2,066,727
Accrued interest	521,030	524,294
Current portion of notes payable	664,217	789,217
Convertible notes payable	448,202	498,202
Total current liabilities	3,833,468	3,878,440
Stockholders' deficit		
Escrow receivable		(227,300)
Additional paid-in capital	2,254,363	579,363
Common stock, no par value, authorized 100,000,000 shares; 88,657,885 and 76,456,095 shares issued and outstanding at March 31, 2004 and December 31, 2003	12,988,627	12,546,957
Accumulated deficit prior to development stage	(1,399,577)	(1,399,577)
Deficit accumulated during the development stage	(17,068,571)	(14,930,259)
Total stockholders' deficit	(3,225,158)	(3,430,816)
Total liabilities and stockholders' deficit	\$ 608,310	\$ 447,624

See notes to condensed consolidated financial statements

**Table of Contents**

MEDICAL DISCOVERIES, INC. AND SUBSIDIARIES  
(A DEVELOPMENT STAGE COMPANY)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
For the Periods Ended March 31, 2004 and March 31, 2003, and Cumulative Amounts  
(Unaudited)

	For the Three Months Ended March 31,		Cumulative Amounts Since November 20, 1991 (Date of Inception)
	2004	2003	
Revenues	\$	\$	\$ 157,044
Cost of goods sold			14,564
	_____	_____	_____
Gross profit			142,480
Research and development expenses	38,643		3,037,288
Inventory writedown			96,859
Impairment loss			9,709
License			1,001,500
General and administrative expenses	2,047,693	147,201	14,167,234
	_____	_____	_____
Operating loss	(2,086,336)	(147,201)	(18,170,110)
Other income (expense)			
Interest income	1,700		25,106
Other income			880,484
Interest expense	(53,676)	(58,033)	(1,039,587)
Forgiveness of debt			1,235,536
	_____	_____	_____
	(51,976)	(58,033)	1,101,539
	_____	_____	_____
Net loss	\$ (2,138,312)	\$ (205,234)	\$(17,068,571)
	_____	_____	_____
Net basic and diluted loss per share	\$ (0.03)	\$ (0.00)	
	_____	_____	
Weighted average shares outstanding	84,830,304	55,598,856	
	_____	_____	



**Table of Contents**

MEDICAL DISCOVERIES, INC. AND SUBSIDIARIES  
(A DEVELOPMENT STAGE COMPANY)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS  
For the Three Months Ended March 31, 2004, March 31, 2003, and Cumulative Amounts  
(Unaudited)

	For the Three Months Ended March 31,		Cumulative Amounts Since November 20, 1991 (Date of Inception)
	2004	2003	
Cash flows from operating activities			
Net loss			
Adjustments to reconcile net loss to net cash used by operating activities			
Common stock options issued for services			3,136,253
Common stock issued for services, expenses, and litigation	52,466		4,253,682
Stock compensation expense	1,675,000		1,675,000
Reduction of escrow receivable from research and development			272,700
Reduction of legal costs			(130,000)
Notes payable issued for litigation			385,000
Depreciation			100,271
Write-off of subscription receivables			112,500
Impairment loss on assets			9,709
Loss on disposal of equipment			30,364
Gain on debt restructuring			(1,235,536)
Write-off of receivables			193,965
Changes in assets and liabilities			
Prepaid expenses	11,331	(26,445)	(1)
Deferred charges	12,077	12,076	1
Accounts receivable			(7,529)
Inventory			
Other assets			
Accounts payable	133,292	64,634	2,044,110
Accrued expenses	(3,264)	42,082	542,511
	<hr/>	<hr/>	<hr/>
Net cash used by operating activities	(257,410)	(112,887)	(5,685,571)
Cash flows from investing activities			
Purchase of equipment			(132,184)
Payments received on note receivable			130,000
	<hr/>	<hr/>	<hr/>



Edgar Filing: MEDICAL DISCOVERIES INC - Form 10QSB/A

Net cash used by investing activities			(2,184)
Cash flows from financing activities			
Contributed equity			131,374
Issuance of common stock	441,504		4,586,163
Payments on notes payable		(25,000)	(231,287)
Proceeds from notes payable		225,000	1,336,613
Payments on convertible notes payable			(98,500)
Proceeds from convertible notes payable			571,702
	<u>441,504</u>	<u>200,000</u>	<u>6,296,065</u>
Net cash provided by financing activities			
Net increase in cash	184,094	87,113	608,310
Cash, beginning of period	424,216	14,555	
	<u>424,216</u>	<u>14,555</u>	<u>608,310</u>
Cash, end of period	\$ 608,310	\$ 101,668	\$ 608,310
	<u>\$ 608,310</u>	<u>\$ 101,668</u>	<u>\$ 608,310</u>
Supplemental disclosure of non-cash activities			
Retirement of notes payable of common stock	\$175,000		

See notes to condensed consolidated financial statements

**Table of Contents**

**MEDICAL DISCOVERIES, INC. AND SUBSIDIARIES  
(A Development Stage Company)**

**NOTES TO UNAUDITED FINANCIAL STATEMENTS  
March 31, 2004**

**Note 1. Basis of Presentation.**

*Unaudited Interim Financial Statements*

The accompanying unaudited financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments and disclosures necessary to a fair presentation of these financial statements have been included. These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's 2003 Annual Report on Form 10-KSB for the year ended December 31, 2003, as filed with the Securities and Exchange Commission. Certain reclassifications and other corrections for rounding have been made in prior period financial statements to conform to the current period presentation. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation.

*Stock Based Compensation and Restatement*

The Company has two incentive stock option plans wherein 24,000,000 shares of the Company's common stock can be issued. The Company granted 700,000 fully vested stock options during the quarter ended March 31, 2004 to consultants with an exercise price of \$.05. These options were valued at \$98,000 using the Black Scholes pricing model using the following weighted average assumptions: risk free interest of 3.8%, expected dividend yield of 0%, volatility of 220% and an expected life of 7 years.

During the first quarter of 2004, the Company extended the expiration date of options to purchase an aggregate amount of 18,403,000 shares of stock. As a result of such extension, such options expire from between 2011 to 2013. Initially we reported that due to the change in expiration date, the options would be subject to variable accounting treatment and would be revalued at the end of each quarter for the life of the option. However, we have subsequently determined that the options are not subject to variable accounting treatment, but instead to a one-time remeasurement of the options as if they were newly granted. The expense associated with the change in expiration date was \$1,577,000.

In October 1995, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 123, which established financial accounting and reporting standards for stock-based compensation. This standard defines a fair value method of accounting for an employee stock option or similar equity instrument. In December 2002, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 148, which revised certain provisions of adopting a fair value method of accounting for stock options and required certain additional disclosures regarding stock options. These statements give entities the choice between adopting the fair value method or continuing to use the intrinsic value method under Accounting Principles Board (APB) Opinion No. 25 with footnote disclosures of the pro forma effects if the fair value method had been adopted. The Corporation has opted for the latter approach.

The Company accounts for its stock options under Accounting Principles Board (APB) Opinion No. 25 using the intrinsic value method. The Company has elected not to adopt the provisions of Statement of Financial Accounting Standards No. 123, Accounting for Stock-Based Compensation (FAS 123). In accordance with Financial Accounting Standards (SFAS) No. 148, Accounting for Stock-Based Compensation Transition and Disclosure, pro-forma net income, stock-based compensation expense, and earnings per share using the fair value method are stated as follows:

	<b>Three Months Ended March 31,</b>	
	<b>2004</b>	<b>2003</b>
Net loss applicable to common stockholders, as reported	\$(2,138,312)	\$(205,234)
Add: Stock-based employee compensation expense included in reported net loss	1,577,000	
Deduct: Total stock based employee compensation expense determined under fair value based method for all awards	<u>(1,916,768)</u>	<u>(5,000)</u>
Pro forma net loss applicable to common shareholders	\$(2,478,080)	\$(210,234)
Basic and diluted loss per share, as reported	\$ (.03)	\$ (.00)
Basic and diluted loss per share, pro forma	\$ (.03)	\$ (.00)

**Table of Contents**

Assumptions used to calculate the income statement impact of stock options granted as if the Company had adopted FAS 123 were as follows:

	<u>2004</u>	<u>2003</u>
Expected dividend yield		
Risk free interest rate	3.8%	5.00%
Expected volatility	220%	511%
Expected life	7 years	10 years
Weighted average fair value per share	\$ 0.10	\$ 0.04

**Note 2. Going Concern Considerations.**

The Company's recurring losses from the Company's development-stage activities in current and prior years raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible effects on the recoverability and classification of assets or amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. The Company is attempting to raise additional capital to sustain operations. However, there can be no assurance that these plans will be successful.

**Note 3. Commitment Regarding Peregrine Stock.**

Peregrine Properties, LLC, a Utah limited liability company (Peregrine), entered into an agreement to provide \$500,000 to the Company to fund testing and research steps necessary to continue development of MDI-P. The studies were funded through an escrow agent. As of December 31, 2000, the Company had deposited in escrow a single certificate for 5.5 million shares of common stock for these purposes. Through December 31, 2003, Peregrine had funded \$275,800 to the escrow, of which \$272,700 had been disbursed and recorded as research and development expense on the financial statements of the Company. The remaining \$227,300 to be expended under the agreement had been recorded on the balance sheet in equity under the caption escrow receivable. On March 22, 2002, the parties entered into an agreement the result of which was to partially close the escrow agreement to the extent of Peregrine's funding to date. On that date, 3,143,800 shares were distributed to Peregrine and all research conducted to date was disbursed to the Company. As of February 20, 2004, the Company held Peregrine in breach with respect to its remaining funding obligation and terminated the Peregrine research agreement. Company management and legal counsel are in the process of releasing the remaining 2,356,200 shares from escrow, which shares have been cancelled. The Company also wrote off the escrow receivable against common stock.

**Note 4. Issuance of Common Stock.**

During the first quarter of 2005, the company issued 14,558,790 shares of restricted common stock, 1,311,650 of which were issued for services valued at \$52,466, 2,209,540 of which were issued upon the conversion of \$175,000 in debt, and 11,037,600 of which were issued for \$441,504 in cash.

**Table of Contents**

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.**

The purpose of this section is to discuss and analyze our consolidated financial condition, liquidity and capital resources, and results of operations. This analysis should be read in conjunction with the financial statements and notes thereto at pages 2 through 7 and Management's Discussion and Analysis of Financial Condition and Results of Operations contained in our Annual Report on Form 10-KSB for the year ended December 31, 2003 (the "2003 10-KSB").

This section contains certain forward-looking statements that involve risks and uncertainties, including statements regarding our plans, objectives, goals, strategies and financial performance. Our actual results could differ materially from the results anticipated in these forward-looking statements as a result of factors set forth under "Cautionary Statement for Forward-Looking Information and Factors Affecting Future Results" below and elsewhere in this report.

**Overview**

We are a development-stage bio-pharmaceutical company engaged in the research, validation, development and ultimate commercialization of a patented anti-infective technology. Our electrolyzed solution of free radicals represents a novel approach to treating our initial target indication, HIV. We plan in the near future to conclude our pre-clinical work and enter the clinic in our initial target indication. If our HIV clinical trials are successful, we plan to develop this therapy for additional target indications.

Our product, called MDI-P, appears to have the ability to destroy certain viruses, bacteria and fungi without any associated toxicity both in animals and in cell-based assays. We are committed to the development of MDI-P as an anti-infective therapeutic product for in-vitro and in-vivo applications. Our highest priority is to develop and commercialize MDI-P as a pharmaceutical for the treatment of HIV. We are in the process of completing pre-clinical development and plan to file an Investigative New Drug application (IND) with the Food and Drug Administration (FDA) for MDI-P as an HIV treatment. If the FDA approves the IND, we will begin a Phase I clinical test at the Harvard School of Medicine using a protocol designed by Dr. Bruce Dezube. We expect to add additional indications for the use of MDI-P in the future as we complete our pre-clinical development.

To date, we have not generated significant revenues from operations or realized a profit. Through March 31, 2004, we had incurred a cumulative net loss since inception of \$17,068,571. We are currently attempting to secure capital commitments to finance the completion of our pre-clinical analysis, file our IND for MDI-P as an HIV therapeutic, determine additional potential indications for MDI-P, and to otherwise continue research and testing of our technologies in order to secure required approvals to bring products to market. In that we are a development stage company, we will increasingly require additional funding to continue the development of our technology and to finance submittal of our testing and trials to the appropriate regulatory agencies in order to secure approvals for product development and sales.

**Recent Events**

***Asthma Study Confirms Low Toxicity Profile and Efficacy of MDI-P.*** On April 22, 2004, MDI announced the receipt of its second in a series of pre-clinical reports from Dr. Emil Chi, Chairman of the Department of Histopathology at the University of Washington Medical School. This trial, one of several studies on models of disease which mimic human disease, focused on MDI-P as a potential therapeutic agent for the treatment of the symptoms of asthma.

More than 28-million Americans suffer from asthma, a major medical problem requiring medication to open blocked airways and relieve mucus build-up in both acute and chronic asthma attacks. In the late 1990's, Dr. Chi developed a

now-standard mouse model to assess asthma therapeutic agents for efficacy and toxicity. This model is believed to have at least an 80% predictive value of results in humans.

In the study, 36 female mice were examined in a chronic asthma model, using various doses of MDI-P as a therapeutic agent as measured against saline control. Samples of bronchial lavage lung fluid and tissue were taken from all mice, with assays performed in airway mucus build-up and eosinophil infiltration, a prime blood cell measure of asthmatic attacks.

## **Table of Contents**

More than 70% of the MDI-P treated mice exhibited no increase in mucus secretions, comparable with saline control animals, with a marked reduction in eosinophil infiltration. Untreated asthmatic mice, in contrast, had more than a nine-fold increase in mucus build-up as compared with saline controls. Further, no toxicity was found in the MDI-P treated mice.

To the best of our knowledge of other published studies in clearing mucus plugs in the same mouse model, there is no product on the market or soon to be released from pharmaceutical pipelines which accomplishes a similar clearing of mucus plugs in the majority of treated chronic asthmatic mice. From this test, we speculate that MDI-P may prove to be a very beneficial agent exhibiting minimal toxicity for addressing asthma attacks.

This study and the other pre-clinical studies of MDI-P are required for filing our Investigational New Drug (IND) application later this year with the FDA for our primary target use for MDI-P, which is treating humans with HIV. These studies test MDI-P on animal models of diseases which mimic those of humans. There is not an animal test relevant to HIV/AIDS in humans, so we are testing MDI-P on other standard animal/mimicking human models, such as our recently-reported sepsis results, in order to determine if there is any potentially significant toxicity to humans related to usage of MDI-P. This report, in addition to other preclinical reports and our CMC/CGMP data, will allow us to file an IND with the FDA for our initial target indication, HIV, and enter clinical trials sometime late in 2004 or early in 2005, continuing the path to commercialization.

We have filed a patent application covering the use of MDI-P to treat asthma.

***Additional Secured Debt Eliminated from Balance Sheet.*** As a result of a negotiated transaction, in April 2004 we were able to eliminate approximately \$130,000 of secured debt from our balance sheet. The transaction converted a secured promissory note in the original principal amount of \$125,000, plus accrued interest, to common stock.

## **Results of Operations**

***Revenues and Gross Profit.*** We did not book any revenue for the quarters ended March 31, 2004 or March 31, 2003. As we continue to pursue pre-clinical and clinical testing of MDI-P as a pharmaceutical for the treatment of HIV as well as other pre-commercialization testing of our technologies, we do not anticipate booking significant revenues in the near future.

***Operating Expenses and Operating Loss.*** We spent \$38,643 on research and development for the quarter ended March 31, 2004, on preclinical tests of MDI-P. We did not have any research and development expenses for the same period of 2003. Our general and administrative expenses were \$2,047,693 during the first quarter of 2004, as compared to \$147,201 during the quarter ended March 31, 2003. The large general and administrative expenses for the first quarter of 2004 was due to a one-time non-cash charge of \$1,577,000 as a result of extending the expiration date of options outstanding. As a result of the foregoing, we sustained an operating loss of \$2,086,336 for the quarter ended March 31, 2004, as compared with an operating loss of \$147,201 for the same period of 2003.

***Other Income/Expense and Net Loss.*** We booked \$1,700 in interest income and incurred interest expenses of \$53,676 for the quarter ended March 31, 2004, as compared with no interest income and \$58,033 in interest expenses for the same period of 2003. In sum, our net loss for the first quarter of 2004 was \$2,138,312 or a loss of \$0.03 per fully diluted share. For the quarter ended March 31, 2003, we incurred a net loss of \$205,234, a loss of less than \$0.01 per fully diluted share.

***Future Expectations.*** We expect to operate at a loss for several more years while we continue to study, gain regulatory approval of and commercialize our technologies. We will spend more in 2004 in research and development expenses as we continue to implement our commercialization strategy. Similarly, we expect our general and

administrative expenses to increase in 2004 as we seek patent protection relating to our pre-clinical progress on MDI-P. As a result, we expect to sustain a greater net loss in 2004, than we have in recent years.

### **Liquidity and Capital Resources**

As of March 31, 2004, we had \$608,310 in cash and had a working capital deficit of \$3,225,158. Since our inception, we have financed our operations primarily through private sales of equity and the issuance of convertible and non-convertible notes. We will require



## **Table of Contents**

significant additional funding to continue to develop, research and seek regulatory approval of our technologies. We do not currently generate any cash from operations and have no credit facilities in place or available. Currently, we are funding operations through issuances of private equity and short-term loans from shareholders and others.

We are seeking to raise substantial additional funds in private stock offerings in order to meet our near-term and mid-term funding requirements. While we are optimistic that we can raise such funds, we have not always been successful in doing so in recent years. In addition, we currently do not have any shares available to issue for these purposes and are seeking at our annual meeting of shareholders scheduled for May 21, 2004, approval from our shareholders to increase our authorized shares. Given that we are still in an early development stage and do not have revenues from operations, raising equity financing is difficult. In addition, any additional equity financing will have a substantial dilutive effect to our current shareholders.

Pursuant to our commercialization strategy, we estimate we will need to expend an additional \$500,000 in research and development to file an IND application with the FDA for MDI-P as an HIV therapy. In addition, we estimate we will need to expend an additional \$300,000 to \$475,000 in debt service and general and administrative costs between now and when we hope to file the IND in Q4 2004 or Q1 2005. Given our current cash position, we are between \$200,000 and \$375,000 short to advance our highest priority target, HIV, to the next development milestone.

Once our IND application is submitted, and assuming it is approved, we will need additional capital to initiate Phase I clinical trials and progress through FDA clinical testing toward the end of a drug that is approved for marketing and sales. We estimate the cost to complete Phase I and Phase II clinical trials to be several million dollars and the cost to complete Phase III testing and obtain approval of an NDA to be in the tens of millions of dollars.

While our ability to obtain financing may improve in the event our IND application is approved, we cannot give assurances that we will have the access to the significant capital required to take a drug through regulatory approvals and to market. We may seek a partner in the global pharmaceutical industry to help us co-develop, license, or even purchase some or all of our technologies.

### **Off-Balance Sheet Arrangements**

We have no off-balance sheet arrangements as defined in Item 303(c) of Regulation S-B.

### **Cautionary Statement for Forward Looking Information**

Certain information set forth in this report contains forward-looking statements within the meaning of federal securities laws. Forward looking statements include statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, and financing needs and other information that is not historical information. When used in this report, the words estimates, expects, anticipates, forecasts, plans, believes and variations of such words or similar expressions are intended to identify forward-looking statements. Additional forward-looking statements may be made by us from time to time. All such subsequent forward-looking statements, whether written or oral and whether made by us or on our behalf, are also expressly qualified by these cautionary statements.

Our forward-looking statements are based upon our current expectations and various assumptions. Our expectations, beliefs and projections are expressed in good faith and are believed by us to have a reasonable basis, including without limitation, our examination of historical operating trends, data contained in our records and other data available from third parties, but there can be no assurance that our expectations, beliefs and projections will result or be achieved or accomplished. Our forward-looking statements apply only as of the date made. We undertake no obligation to publicly update or revise forward-looking statements which may be made to reflect events or circumstances after the date made

or to reflect the occurrence of unanticipated events.

There are a number of risks and uncertainties that could cause actual results to differ materially from those set forth in, contemplated by or underlying the forward-looking statements contained in this report. Those risks and uncertainties include, but are not limited to, our lack of significant operating revenues and lack of profit to date, our need for substantial and immediate additional capital, the fact that we may dilute existing shareholders through additional stock issuances, the extensive governmental regulation to which we are subject, the fact that our technologies remain unproven, the intense competition we face from other companies and other products, and our reliance upon potentially

**Table of Contents**

inadequate intellectual property. Those risks and certain other uncertainties are discussed in more detail in the 2003 10-KSB. There may also be other factors, including those discussed elsewhere in this report, that may cause our actual results to differ from the forward-looking statements. Any forward-looking statements made by us or on our behalf should be considered in light of these factors.

**ITEM 3. CONTROLS AND PROCEDURES**

(a) Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-14(c) promulgated under the Securities Exchange Act of 1934, as amended (the Exchange Act ), as of March 31, 2004. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2004.

(b) There have been no significant changes (including corrective actions with regard to significant deficiencies or material weaknesses) in our internal controls or in other factors that could significantly affect these controls subsequent to the date of the evaluation referenced in paragraph (a) above.

**PART II  
OTHER INFORMATION**

**ITEM 2. CHANGES IN SECURITIES**

(c) We sold the following unregistered securities during the period covered by this report. None of the sales involved an underwriter. We believe these sales were exempt from registration pursuant to Section 4(2) of the Securities Act of 1933 because the sales did not involve a public offering.

11,037,600 shares of restricted common stock at \$0.04 per share.

**ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K**

(a) Exhibits.

The following documents are furnished as exhibits to this Form 10-QSB. Exhibits marked with an asterisk are filed herewith. The remainder of the exhibits previously have been filed with the Commission and are incorporated herein by reference.

<b>NUMBER</b>	<b>EXHIBIT</b>
3.1	Amended and Restated Articles of Incorporation of the Company (filed as Exhibit 3.1 to the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 1994, and incorporated herein by reference).
3.2	Amended Bylaws of the Company (filed as Exhibit 3.2 to the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 1994, and incorporated herein by reference).
10.1	Employment Agreement dated as of May 15, 2002 between Medical Discoveries, Inc. and Judy M. Robinett (filed as Exhibit 10.4 to the Company's Quarterly Report on Form 10-QSB for the quarter ended June 30, 2002, and incorporated herein by reference).

- 10.2 2002 Stock Incentive Plan adopted by the Board of Directors as of July 11, 2002 (filed as Exhibit 10.5 to the Company's Quarterly Report on Form 10-QSB for the quarter ended June 30, 2002, and incorporated herein by reference).
- 31 Rule 13a-14(a) Certification, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. \*
- 32 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\*

(b) Reports on Form 8-K.

The Company filed Current Reports on Form 8-K on January 15, 2004, January 21, 2004 and March 18, 2004.

**Table of Contents**

**SIGNATURES**

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MEDICAL DISCOVERIES, INC.

/S/ JUDY M. ROBINETT

---

Judy M. Robinett  
President and Chief Executive Officer

Date: November 15, 2004

**Table of Contents**

**INDEX TO EXHIBITS**

<b>NUMBER</b>	<b>EXHIBIT</b>
3.1	Amended and Restated Articles of Incorporation of the Company (filed as Exhibit 3.1 to the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 1994, and incorporated herein by reference).
3.2	Amended Bylaws of the Company (filed as Exhibit 3.2 to the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 1994, and incorporated herein by reference).
10.1	Employment Agreement dated as of May 15, 2002 between Medical Discoveries, Inc. and Judy M. Robinett (filed as Exhibit 10.4 to the Company's Quarterly Report on Form 10-QSB for the quarter ended June 30, 2002, and incorporated herein by reference).
10.2	2002 Stock Incentive Plan adopted by the Board of Directors as of July 11, 2002 (filed as Exhibit 10.5 to the Company's Quarterly Report on Form 10-QSB for the quarter ended June 30, 2002, and incorporated herein by reference).
31	Rule 13a-14(a) Certification, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
32	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

---

\* Filed herewith.